From: Target fluorescence in-situ hybridization (Target FISH) for plasma cell enrichment in myeloma
No. | Sex/Age | PC%a | BioViewb | Del(17p)/TP53 | t(4;14) | t(14;16) | +1q21 | Others |
---|---|---|---|---|---|---|---|---|
1 | M/52 | 26 % | 14–16 % (10323–15875) | Neg (230)c | 38 % + (74) | Neg (201) | 30 % + (180) | |
2 | F/80 | 15 % | 3–4 % (9605–13508) | Neg (89) | Neg (61) | Neg (71) | Neg (71) | Normal cytogenetics |
3 | M/69 | 12 % | 3–4 % (8880–11094) | Neg (84) | Neg (46)g | Neg (40)g | Neg (62) | |
4 | M/81 | 43 % | No record | Neg (253) | Neg (188) | Neg (175) | Neg (200) | 5/9/15 60 % + (235) |
5 | M/64 | 15 % | 58–64 % (11912–17007) | Neg (159) | Neg (153) | Neg (156)g | Neg (155) | 5/9/15 Neg (84) |
6 | M/70 | 17 % | 4–7 % (7132–7616) | Neg (63) | Neg (53)g | Neg (51)g | 80 % + (53) | 5/9/15 Neg (61) |
7 | F/52 | 35 % | 8–12 % (7750–8981) | Neg (159) | 90 % + (112)g | Neg (102)g | 65 % + (167) | Cytogeneticsd: hypodiploid 78.5 %, hyperdiploid 7 %, normal 14.5 % |
8 | F/72 | 13 % | 42–55 % (11829–14627) | Neg (32) | Neg (35) | Neg (71) | Neg (54) | |
9 | F/71 | 17 % | 7–9 % (8667–11174) | Neg (82) | 70 % + (54) | Neg (37) | 50 % + (65) | Normal cytogenetics |
10 | M/61 | 65 % | 17–24 % (10289–13997) | Neg (135) | Neg (94)g | Neg (98)g | 90 % + (145) | |
11 | M/54 | 15 % | 15–22 % (12898–19268) | Neg (141) | 80 % + (87) | Neg (84) | Neg (113) | 5/9/15 Neg (171) |
12 | M/47 | 100 % | 50–59 % (10424–12419) | 50 % + (132) | Neg (144)g | Neg (107)g | Neg (156) | |
13 | M/59 | 60 % | 10–12 % (9514–13412) | Neg (154) | Neg (133)g | Neg (128)g | Neg (140) | t(11;14) 90 %+; normal cytogenetics |
14 | M/81 | 22 % | 50–52 % (10110–15964) | Neg (140) | 60 % + (78)g | Neg (111)g | 85 % + (172) | 5/9/15 Neg (101) |
15 | F/67 | 45 % | 21–27 % (6066–7366) | Neg (163) | 90 % + (145) | Neg (136) | 85 % + (183) | 5/9/15 Neg (157) |
16 | M/58 | No record | 8–9 % (6666–8923) | Neg (250) | Neg (192)g | Neg (188)g | Neg (224) | t(11;14) 25 % + (228) |
17 | F/70 | 51 % | 13–17 % (7469–8551) | Neg (183) | Neg (137)g | Neg (118)g | 85 % + (162) | Normal cytogenetics |
18 | F/53 | 23 % | 10 % (2719–4195) | Neg (198) | Neg (146) | Neg (80) | Neg (106) | 5/9/15 Neg (87) |
19 | M/76 | 70 % | 6–7 % (4145–5686) | Neg (108) | Neg (89) | Neg (102) | Neg (101) | IgH Neg (71) |
20 | M/61 | 49 % | 17–19 % (4210–5352) | Neg (170) | Neg (126) | Neg (119) | 85 % + (172) | |
21 | M/61 | 20 % | 24–29 % (9895–11736) | Neg (145) | Neg (122) | Neg (87) | Neg (142) | Normal cytogenetics |
22 | F/48 | 59 % | 6–9 % (6942–7583) | 40 % + (172) | 65 % + (110) | Neg (111) | 55 % + (154) | Normal cytogenetics |
23 | F/56 | 100 % | 3–8 % (4400–6203) | Neg (123) | Neg (149)g | Neg (118) | 65 % + (158) | |
24 | F/55 | 84 % | 3–6 % (9304–10362) | Neg (141) | Neg (148) | Neg (107) | Neg (82) | t(11;14) 85 % + (121) |
25 | M/52 | 74 % | 11–23 % (10024–12394) | Neg (158) | 85 % + (100) | Neg (135)g | 90 % + (162) | Cytogeneticse: hypodiploid clone, der(4)t(1;4)(q21;p16) and add(7p) |
26 | F/56 | 35 % | 11–17 % (10247–12375) | Neg (100) | Neg (166) | Neg (140)g | Neg (117) | |
27 | F/55 | 73 % | 10–17 % (3419–5581) | Neg (186) | Neg (167) | Neg (142) | Neg (171) | |
28 | F/57 | 15 % | 6–8 % (5191–6330) | Neg (102) | Neg (122) | Neg (102) | Neg (100) | |
29 | F/69 | 16 % | 25–32 % (7923–12371) | Neg (172) | Neg (143)g | Neg (104)g | Neg (173) | |
30 | M/58 | 19 % | 3–5 % (6385–8924) | Neg (213) | Neg (169) | Neg (154) | Neg (208) | |
31 | F/66 | 29 % | 7–11 % (7383–9153) | Neg (149) | 70 % + (73) | Neg (108)g | 80 % + (127) | |
32 | F/56 | 15 % | 7–12 % (11256–13079) | Neg (146) | Neg (117)g | Neg (93) | Neg (150) | |
33 | M/64 | 13 % | 4–6 % (11082–12940) | Neg (118) | Neg (100) | Neg (98) | Neg (101) | t(11;14) 40 % + (149); cytogeneticsf: loss of Y chromosome |
34 | F/67 | 21 % | 6–13 % g11872–14598) | Neg (159) | 70 % + (104) | Neg (118)g | 95 % + (136) | |
35 | F/89 | 12 % | 3–5 % (11793–14289) | Neg (121) | Neg (134) | Neg (102) | Neg (102) | Normal cytogenetics |
36 | F/50 | 56 % | 14–17 % (10614–13489) | Neg (140) | Neg (143) | Neg (111) | 60 % + (137) | |
37 | M/60 | 50 % | 24–27 % (10633–13622) | Neg (165) | Neg (121) | Neg (117) | 83 % + (143) | |
38 | M/79 | 20 % | 6–10 % (13896–15969) | Neg (125) | Neg (96) | Neg (121)g | 80 % + (144) | 80 % trisomy TP53 |
39 | F/67 | 53 % | 32–38 % (13807–17047) | Neg (162) | 63 % + (123) | Neg (103) | 63 % + (104) | |
40 | M/69 | 57 % | 6–13 % (12778–15272) | Neg (158) | Neg (127) | Neg (148) | Neg (158) |